Bronchopulmonary carcinoid: Phenotype and long-term outcome in a single-institution series of Italian patients

Clinical Cancer Research

Volumn 14, Issue 1, 2008, Pages 149-154

  Rugge, Massimo ^a,c,d,e   Fassan, Matteo ^a   Clemente, Roberto ^d   Rizzardi, Giovanna ^b   Giacomelli, Luciano ^e   Pennelli, Gianmaria ^a,d   Mescoli, Claudia ^a   Segat, Daniela ^c   Rea, Federico ^b  

^a Pathology Unit   (Italy)

^b Thoracic Surgery Unit   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; KI 67 ANTIGEN; NEURON SPECIFIC ENOLASE; PROTEIN BAX; PROTEIN BCL 2; THYROID TRANSCRIPTION FACTOR 1;

ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHUS CARCINOID; CANCER CENTER; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITOSIS RATE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; CARCINOID TUMOR; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ITALY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PROGNOSIS; RESPIRATORY TRACT NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 40749122150     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1631     Document Type: Article

References (45)

1. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001;119:1647-51.
2. Hage R, de la Riviere AB, Seldenrijk CA, van den Bosch JM. Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol 2003;10:697-704.
3. Beasley MBTF, Hasleton PhS, Barbareschi M, et al. Carcinoid tumour. In: Travis WD BE, Muller-Hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon (France): IARC Press; 2004. p. 59-62.
4. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-44.
5. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000;31:1255-65.
6. Cai YC, Banner B, Glickman J, Odze RD. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol 2001;32:1087-93.
7. Du EZ, Goldstraw P, Zacharias J, et al. TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum Pathol 2004;35:825-31.
8. Saqi A, Alexis D, Remotti F, Bhagat G. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 2005;123:394-404.
9. Helpap B, Kollermann J. Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence? Virchows Arch 2001;438:86-91.
10. Baak JP. Mitosis counting in tumors. Hum Pathol 1990;21:683-5.
11. Laitinen KL, Soini Y, Mattila J, Paakko P. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity. Cancer 2000;88:1590-8.
12. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 1996;62:798-809.
13. Pujol JL, Simony J, Jolimoy G, et al. Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers. Br J Cancer1996;74:964-70.
14. Bohm J, Koch S, Gais P, Jutting U, Prauer HW, Hofler H. Prognostic value of MIB-1in neuroendocrine tumours of the lung. J Pathol 1996;178:402-9.
15. Santinelli A, Ranaldi R, Baccarini M, Mannello B, Bearzi I. Ploidy, proliferative activity, p53a nd bcl-2 expression in bronchopulmonary carcinoids: relationship with prognosis. Pathol Res Pract 1999;195:467-74.
16. Lin O, Olgac S, Green I, Zakowski MF, Klimstra DS. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. Am J Clin Pathol 2003;120:209-16.
17. Costes V, Marty-Ane C, Picot MC, et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study. Hum Pathol 1995;26:740-5.
18. Granberg D, Wilander E, Oberg K, Skogseid B. Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab 2000;85:3425-30.
19. Lohmann DR, Fesseler B, Putz B, et al. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res 1993;53:5797-801.
20. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-52.
21. Coppola D, Clarke M, Landreneau R, Weyant RJ, Cooper D, Yousem SA. Bcl-2, p53 , CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung. Mod Pathol 1996;9:484-90.
22. Zirbes TK, Lorenzen J, Baldus SE, et al. Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung. Histopathology 1998;33:123-8.
23. Wang DG, Johnston CF, Sloan JM, Buchanan KD. Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53. J Pathol 1998;184:247-51.
24. Jass JR, Ajioka Y, Allen JP, et al. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology1996;28:543-8.
25. Leandro G, Duca P. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area: a case-control study. Cancer 1993;71:510-1.
26. Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour KA, Miller JI. The surgical spectrumof pulmonary neuroendocrine neoplasms. Chest 2001;119:14-8.
27. Garcia-Yuste M, Matilla JM, Cueto A, et al. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 2007;31:192-7.
28. Soga J, Yakuwa Y. Bronchopulmonary carcinoids: an analysis of 1,875 reported caseswith special reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg 1999;5:211-9.
29. Thomas CF, Jr., Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement. Chest 2001;119:1143-50.
30. Ferguson MK, Landreneau RJ, Hazelrigg SR, et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg 2000;18:156-61.
31. Okike N, Bernatz PE, Woolner LB. Carcinoid tumors of the lung. Ann Thorac Surg 1976;22:270-7.
32. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15:529-53.
33. Barbareschi M, Girlando S, Mauri FA, et al. Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. J Pathol 1992;166:343-50.
34. Bonato M, Cerati M, Pagani A, et al. Differential diagnostic patterns of lung neuroendocrine tumours. A clinico-pathological and immunohistochemical study of 122 cases. Virchows Arch A Pathol Anat Histopathol 1992;420:201-11.
35. Fabbro D, Di Loreto C, Stamerra O, Beltrami CA, Lonigro R, Damante G. TTF-1 gene expression in human lung tumours. Eur J Cancer 1996;32A:512-7.
36. Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999;12:5- 8.
37. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 2000;36:415-20.
38. Oliveira AM, Tazelaar HD, Myers JL, Erickson LA, Lloyd RV. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 2001;25:815-9.
39. Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrumof neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002;33:175-82.
40. Schreurs AJ, Westermann CJ, van den Bosch JM, Vanderschueren RG, Brutel de la Riviere A, Knaepen PJ. A twenty-five-year follow-up of ninety-three resected typical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1992;104:1470-5.
41. Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005;29:179-87.
42. Kobayashi Y, Tokuchi Y, Hashimoto T, et al. Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors. Cancer Sci 2004;95:334-41.
43. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1972;64:413-21.
44. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-60.
45. Arbiser ZK, Arbiser JL, Cohen C, Gal AA. Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis. Mod Pathol 2001;14:1195- 9.